ESVS 2016 – København

ESVS 2016 – København

Knut E. Kjørstad (UNN) presenterte resultatene fra carotisstudien på ESVS 2016 i København.

Under carotis-kirurgi seansen under ESVS 2016 i København ble de endelige resultatene presentert for et internasjonalt karkirurgisk miljø.

Abstrakt (kilde: ESVS 2016 Book of Abstract)


Institution: 1. University Hospital of North Norway, Tromsø 2. Haugesund Hospital, Haugesund 3. Østfold Hospital, Fredrikstad 4. Vestfold Hospital, Tønsberg 5. Molde Hospital, Molde 6. Bodø Hospital, Bodø 7. Oslo University Hospital, Oslo 8. Haukeland University Hospital, Bergen 9. Hamar Hospital, Hamar 10. Drammen Hospital, Drammen 11. Akershus University Hospital, Lørenskog 12. Ålesund Hospital, Ålesund 13. Stavanger University Hospital, Stavanger 14. St. Olav’s University Hospital, Trondheim, Norway

Authors presenting: Knut Eivind Kjørstad, Svein T. Baksaas, Dorte Bundgaard, Erik Halbakken, Terje Hasselgård, Geir T. Jørgensen, Anne H. Krog, Kirsten Krohg-Sørensen, Elin Laxdal, Sven R. Mathisen, Gudmundur V. Oskarsson, Synnøve Seljeskog, Inge Settemsdal, Beate Viddal, Frode Aasgaard, Erney Mattsson

Introduction: Recommendations for timing of surgical treatment of symptomatic carotid stenosis vary from within 48 hours (UK) to within 2 weeks ( Norway) from onset of symptoms. The aim of the study was to observe all patients in Norway operated upon for symptomatic carotid stenosis during one year with respect to; 1) the time from the index event to surgery and its neurological consequences, 2) the level in the health care system causing delay in surgical treatment, and 3) the possible relation between perioperative use of platelet inhibitors and recurrent neurological symptoms.

Methods: All 15 hospitals in Norway performing carotid endarterectomy (CEA) contributed to this prospective national multicenter study. Patients were included when referred to surgery, and after written informed consent was obtained. We defined the index event as the neurological event promoting contact with the health care system. Results: 371 patients were eligible for inclusion between April 1st 2014 and March 31st 2015, and 368 patients (99.2 %) were included. The index events were; minor stroke in 39.4 %, transitory ischemic attack in 36.7 %, amaurosis fugax in 17.4 %, and major stroke in 6.0 % of the patients. 54 % of the patients contacted their family doctor on the day of the index event. The primary health care referred 84.2 % of the patients to hospital on the same day as examined. In-hospital median time from arrival to referral for vascular surgery was three days, and after seven days 82.9 % of the patients had been referred. Median time between referral to the operative unit and actual CEA was five days, and 10 days after referral to vascular surgery 81.5 % had been operated. Overall, 61.7 % of the patients were operated within 2 weeks after the index event (see figure). There were no deaths between referral for surgery and time of CEA, but 25 patients (6.8 %) suffered a new neurological event while waiting for surgery. Less than half of the patients (44.0 %) who suffered a new neurological event were on a platelet inhibitor other than ASA. Among those that did not face a new neurological event the percentage was 74.6 (p = 0.01, Pearson’s Chi-Square test). There was no difference between the two groups with respect to use of ASA. Thirteen patients (3.5 %) suffered a perioperative stroke (6 major and 7 minor), and the 30-day mortality rate was 0.5 %. The combined 30-day mortality and stroke rate was 3.8 %. Nearly all patients were controlled one month or later after discharge (99.2%). Seven patients (1.9 %) had persistent signs of peripheral nerve injury at the control. No patients showed signs of new neurological events.

Conclusion: This national study with almost complete inclusion and follow up shows a delay emerging at the level of the patient and in-hospital, including the departments of vascular surgery. The delay is connected with new neurological symptoms. Use of a second platelet inhibitor other than ASA is associated with reduced risk of having a new neurological event after symptom debut.